PropertyValue
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/ns/prov#value
  • efficacy; the risk that, even if clinical studies are successful, the FDA, the EMA or other regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication are successful, clinical studies in another indication may not be successful; the potential for unsuccessful nonclinical or clinical studies in one
http://www.w3.org/ns/prov#wasQuotedFrom
  • masttherapeutics.com